Setidegrasib Shows Early Promise in Advanced Lung and Pancreatic Cancers
Setidegrasib, a novel KRAS G12D-targeted protein degrader, showed promising tumor responses in pancreatic and lung cancers, advancing precision oncology and personalized cancer treatment strategies.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.